News and Trends 22 Jun 2020
Swedish Biotech’s Psoriasis Drug Beats Placebo in Phase II
A new class of drug developed by the Swedish biotech company Affibody has proved better at treating symptoms of psoriasis than a placebo in a phase II trial, leading the company to develop the candidate for other conditions such as uveitis and psoriatic arthritis. The phase II study enlisted 108 patients with psoriasis, a chronic […]